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Introduction:  To assess the impact of statin use on 
biochemical recurrence (BCR) of prostate cancer after 
radical prostatectomy (RP).
Materials and methods:  Data from all men treated 
with robot-assisted laparoscopic RP (RALRP) for localized 
prostate cancer between 2009 and 2014 at our institution 
were prospectively collected: age, body mass index 
(BMI), statin-use status, preoperative prostate-specific 
antigen (PSA) level, clinical T stage, biopsy Gleason 
score (bGS), D’Amico risk group, pathological T stage, 
specimen Gleason score (sGS), multifocality, peri neural 
invasion, positive surgical margins and time to BCR. 
Univariate and multivariate analysis were performed to 
test associations between statin use and prognostic factors 
of prostate cancer and/or BCR.
Results:  Overall, 591 patients with a median follow up 
of 42.3 months [25.8-59.9] were included in the current 
study and split in two cohorts: statin users (n = 156) 
and statin non-users (n = 435).  When comparing 
statin user and non-users, no significant difference was 
found in terms of clinical, biochemical and pathological 
characteristics except for BMI (median 29 versus 26, 
respectively; p = 0.04).  Regarding BCR, there was no 
significant difference between men using statin versus 
those not using them (4.5% versus 4.6%, p = 0.65). 
In univariate analysis, statin use was not significantly 
correlated to any prognostic factors of prostate cancer 
recurrence.  Furthermore, there was no significant 
difference in the 5 years biochemical-free survival rates 
between statin users and non-users (75% versus 73%; 
p = 0.7).
Conclusions:  From the current study, statin daily intake 
was not significantly associated with any prognostic 
factors of prostate cancer and with BCR after RARLP.
Key Words:  hydroxymethylglutaryl-CoA reductase 
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10% (29,480) of cancer related deaths in 2014 in the 
United States.1  Despite ongoing debates regarding 
both overdiagnosis and overtreatment of prostate 
cancer, patients presenting with decent life expectancy 
are still candidates for curative treatment such as 
radical prostatectomy (RP) that remains one of the 
gold standard treatment in men between 50 and 70 
years.2  However, up to 40% of patients will experience 
biochemical recurrence (BCR) after first-line surgical 
treatment of prostate cancer.3 
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Introduction
Prostate cancer is a widespread male neoplasm that 
has recently been recognized to account for 27% 
(233,000) of newly diagnosed cases of cancer and 
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Interestingly, a specific concern has been recently 
raised regarding a possible correlation between 
statin use in these men and the risk of BCR after 
definitive local therapy of prostate cancer.  Statins are 
3-hydroxy-3-methyl-glutaryl coenzyme A (HMGCoA) 
inhibitors that have been increasingly used over the 
past few years giving their indisputable ability to 
significantly improve survival by decreasing deaths 
from cardiovascular disease.4,5  However, there is also 
growing evidence suggesting that statins might have 
a secondary chemoprotective effect against many 
cancers.6  Indeed, several authors have demonstrated 
that statins are able to stop cell-cycle progression, 
induce apoptosis, reduce inflammation and impede 
angiogenesis.7-10  In addition to their lowering 
cholesterol effect resulting in steroid biosynthesis 
inhibition rationally involved in hormone dependent 
cancer progression, statins target the melavonate 
pathway that is intimately related to well-known 
signaling routes of carcinogenesis such as p53.11
The impact of statin use on the natural history of 
prostate cancer has been previously investigated in many 
studies but its real impact still remains controversial.12,13 
Indeed, conflicting results have been reported regarding 
the propensity of statins to prevent carcinogenesis of 
aggressive diseases and also to increase the risk of BCR 
after RP for localized prostate cancer.14-17 
Thus, our purpose was to assess the impact of statin 
use on BCR after RP in localized prostate cancer.
Materials and methods
Population
Data from all consecutive men treated with robot-
assisted laparoscopic radical prostatectomy (RALRP) 
for localized prostate cancer between 2009 and 2014 at 
our institution were prospectively collected in a digital 
database.  Only patients with following available data 
were included in this observational cohort study: age, 
body mass index (BMI), statin-use status, preoperative 
prostate-specific antigen (PSA) level, clinical T stage (cT 
stage), biopsy Gleason score (bGS), D’Amico risk group, 
pathological T stage (pT stage), specimen Gleason score 
(sGS), tumor multifocality (TM), peri neural invasion 
(PNI), positive surgical margins (PSM), BCR status, 
time to BCR and follow up.  Missing preoperative 
and/or follow up data in 186 men were consequently 
exclusion criteria.  No patient received preoperative 
radiotherapy or hormonal treatment.  Statin use at the 
time of diagnosis, regardless of statin dose and type was 
recorded for each patient.  Only men who had taken 
statin for at least 1 year before surgery were included 
in the current study.  The Ethics Committee of the 
Assistance Publique-Hôpitaux de Paris (AP-HP) (i.e., 
IRB approval) approved of the study and the Principles 
of the Declaration of Helsinki were respected.
Intervention
The da Vinci surgical system was used by two referent 
surgeons at our institution to perform RARLP, as 
described previously.18 
Pathological evaluation
All surgical specimens were analyzed by a single referent 
uropathologist.  They were first fixed in a 10% neutral 
buffered formalin and were then cut transversally at 
regular intervals.  Pathological stage was defined using 
the 2009 TNM classification.  Tumor differentiation was 
given according to the surgical Gleason score based on the 
ISUP 2005 criteria.  During the macroscopic examination 
(orientation, weight, size, description) of the surgical 
specimen, the entire surface of the RP specimen was 
covered with ink for an accurate evaluation of surgical 
margins.  Positive surgical margins on pathologic 
evaluation were defined as cancer cells touching the 
inked surgical margins of the RP specimen. 
Follow up
All patients were seen at 3 and 6 months after surgery 
and at least once a year thereafter to assess functional 
outcomes (i.e. potency, urinary continence) and to screen 
for BCR using PSA testing.  Survival was evaluated from 
the date of surgery to the last follow up visit or death. 
According to the current guidelines, BCR was defined 
as two consecutive measures of PSA > 0.2 ng/mL with a 
3 month delay. 2  Consequently, recurrence-free survival 
rate was defined as the time from RALRP to BCR.
Statistical analysis
The Shapiro-Wilk test was used to assess the normal 
distribution of variables.  Then, Student’s t-test and Mann 
Whitney U-test were used to compare normally and non-
normally distributed continuous variables, respectively. 
The chi-square test was used to compare non-normally 
categorical variables.  Associations between statin daily 
intake and prognostic factors commonly used to assess 
prostate cancer outcomes: cT stage, bGS, D’Amico risk 
group, pT stage, sGS, TM, PNI, PSM were tested in 
univariate analysis.  Then, univariate and multivariate Cox 
regression analysis including statin use were performed to 
determine potential independent predictors of BCR and 
estimate their hazard ratios (HR) with 95% IC.  Kaplan 
Meier method and log rank statistics were used to calculate 
biochemical-free survival rates (BFSR).  Statistical values 
were considered significant for a p value < 0.05.  All tests 
were carried out using SPSS, version 12 (Chicago, IL, USA).
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TABLE 1.  Main characteristics of the study population    
Characteristics Overall Statin non users Statin users p value
No. patients (%) 591 (100) 435 (73.6) 156 (26.4) 
Median age (yrs) [IQR]  62.8 [49.1-69.2] 62.4 [49.1-69.2] 63.8 [50.2-69.8] 0.11
Median BMI (kg/m2) [IQR] 26.8 [21.9-34.3] 26.0 [21.1-33.5] 29.0 [23.4-36.0] 0.04
Median preoperative PSA (ng/mL) [IQR] 8.3 [4.1-12.4] 8.4 [4.3-13.7] 7.9 [3.9-11.8] 0.31
No. clinical T stage    0.18
     cT1c 362 (61.2) 265 (60.9) 97 (62.2)
     cT2a 68 (11.5) 49 (11.3) 19 (12.1)
     cT2b 50 (8.5) 36 (8.3) 14 (8.8)
     cT2c 44 (7.5) 33 (7.6) 11 (7.0)
     cT3a 67 (11.3) 52 (11.9) 15 (9.9)
     cT3b 0 (0%) 0 (0%) 0 (0%)
No. biopsy Gleason score (%)     0.47
     ≤ 6 351 (59.4) 258 (59.3) 93 (59.5)
     7 185 (31.3) 136 (31.3) 49 (31.3)
     ≥ 8 55 (9.3) 41 (9.4) 14 (9.2)
No. D’Amico risk group (%)    0.41
     Low 316 (53.5) 232 (53.3) 84 (53.8)
     Intermediate 201 (34.0) 148 (34.0) 53 (34.0)
     High 74 (12.5) 55 (12.7) 19 (12.2) 
Median blood loss (mL) 347.5 [324.8-370.1] 352.2 [324.6-379.7] 334.1 [296.1-372.2] 0.75
No. specimen Gleason score (%)    0.10
     ≤ 6 206 (34.9) 147 (33.8) 59 (37.8)
     7 313 (52.9) 233 (53.6) 80 (51.3)
     ≥ 8 72 (12.2) 55 (12.6) 17 (10.9) 
No. pathological T stage (%)    0.35
     pT2a 27 (4.6) 20 (4.6) 7 (4.7)
     pT2b 19 (3.2) 13 (3.0) 6 (4.2)
     pT2c 381 (64.5) 281 (64.6) 100 (63.9)
     pT3a 133 (64.5) 98 (22.5) 35 (22.1)
     pT3b 31 (5.2) 23 (5.3) 8 (5.1)
No. tumor multifocality (%) 556 (94) 409 (94.1) 147 (94.1) 0.94
No. peri neural invasion (%) 508 (85.9) 374 (86.0) 134 (85.7) 0.84
No. positive surgical margins (%) 87 (14.7) 64 (14.7) 23 (14.7) 0.96
No. biochemical recurrence (%) 27 (4.6) 20 (4.6) 7 (4.5) 0.65
Median time to BCR (months) 18.5 [12.3-25.1] 18.1 [11.6-25.9] 18.9 [13.1-26.2] 0.23
Median follow up (months) [IQR] 42.3 [25.8-59.9] 41.5 [24.1-57.8] 43.7 [26.4-60.2] 0.19
IQR = interquartile range; BMI = body mass index; PSA = prostate-specific antigen; BCR = biochemical recurrence
Results
Population
Overall, 591 patients with a median age of 62.8 
years [IQR 49.1-69.2] were included in the current 
study and split in two different cohorts: statin users 
(n = 156) and statin non users (n = 435).  Demographic 
characteristics of study population are listed in Table 1. 
Median preoperative PSA level was 8.3 ng/mL [IQR 
4.1-12.4] and RALRP was performed on patient with a 
median BMI of 26.8 [IQR 21.9-34.3].  According to the 
D’Amico classification, 316 (53.5%), 201 (34.0%) and 
74 (12.5%) patients were ranked into preoperative low, 
intermediate and high risk groups of prostate cancer, 
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TABLE 2.  Univariate analysis testing associations 
between statin use and clinical, pathological or 
biochemical characteristics commonly used to assess 
disease course of localized prostate cancer after 
robot-assisted laparoscopic radical prostatectomy    
Characteristics                                Statin users  
        versus non users
 HR (95% IC) p value
Preoperative PSA level 0.98 (0.95-1.02) 0.31
Clinical T stage  0.93 (0.82-1.04) 0.26
Biopsy Gleason score 0.94 (0.74-1.19) 0.57
D’Amico risk group 0.91 (0.79-1.07) 0.31
Specimen Gleason score 0.73 (0.54-1.02) 0.08
Pathological T stage 0.89 (0.79-1.08) 0.36
Extra capsular invasion 0.96 (0.62-1.49) 0.85
Seminal vesicles invasion 0.92 (0.84-1.02) 0.17
Multifocality 0.90 (0.51-1.61) 0.73
Peri neural invasion 1.00 (0.62-1.60) 0.99
Positive surgical margins 0.99 (0.59-1.64) 0.96
TABLE 3.  Univariate and multivariate analysis of biochemical recurrence predictors after robot-assisted 
laparoscopic radical prostatectomy for treating localized prostate cancer    
Risk factors Univariate analysis  Multivariate analysis
 HR (95% IC) p value HR (95% IC) p value
Body mass index 0.99 (0.98-1.02) 0.98 - -
Statin use 0.84 (0.36-2.00) 0.70 - -
Preoperative PSA level 1.03 (0.98-1.09) 0.21 - -
Clinical T stage 1.06 (0.95-1.18) 0.37 - -
Biopsy Gleason score  1.82 (1.34-2.48) < 0.001 1.60 (1.02-2.51) 0.04
D’Amico risk group 1.78 (1.21-2.35) 0.02 1.51 (1.24-1.78) 0.01
Specimen Gleason score   2.43 (1.53-3.87) < 0.001 1.94 (1.08-3.01) 0.02
Pathological T stage  2.09 (1.34-3.28) < 0.001 1.79 (0.93-3.43) 0.08
Multifocality 1.86 (0.55-6.32) 0.32 - -
Peri neural invasion 2.25 (0.66-7.57) 0.19 - -
Positive surgical margins 2.53 (1.14-5.66) 0.02 2.82 (1.06-7.05) 0.04
respectively.  In the statin users group, the median 
length of statin intake before surgery was 28.2 months 
[IQR 22.5-36.7].  When comparing statin users with 
non-users, no significant difference was found in terms 
of clinical, biochemical and pathological characteristics 
except for BMI (median 29 versus 26, respectively; 
p = 0.04).  Notably, TM (94.1%; p = 0.94) PSM (14.7%, 
p = 0.96) rates were exactly the same in both groups. 
However, there was no significant difference between 
statins users and non-users according to: preoperative 
stratification in low risk group of prostate cancer risks 
(53.8% versus 53.3% respectively; p = 0.41), or pT2 stage 
diseases on pathologic specimen (73.1% versus 72.2% 
respectively; p = 0.35).  
Statin use and prognostic factors
There was no significant association between statin 
daily intake and clinicopathological features of 
aggressive prostate cancer, see Table 2.
Statin use and BCR
After a median follow up of 42.3 [25.8-59.9] months, 
BCR occurred in 27 (4.6%) patients, Table 1.  Again 
there was no significant difference among statin users 
compared to statin non-users in BCR (4.5% versus 
4.6%, respectively; p = 0.65).  Median time to BCR 
was 18.5 [12.3-25.1] months without any significant 
difference between statin users and non-users (18.9 
versus 18.1, respectively; p = 0.23). 
In univariate analysis, statin intake was not 
significantly associated with a decreased risk of BCR 
compared to the non-user group (HR = 0.84; 95% 
IC = [0.36-2.00]; p = 0.70), see Table 3.  When performing 
multivariate analysis, only bGS (HR = 1.60; 95% 
IC = [1.02-2.51]; p = 0.04), D’Amico risk group (HR = 1.51; 
95% IC = [1.24-1.78]; p = 0.01), sGS (HR = 1.94 95% 
IC = [1.08-3.01]; p = 0.02) and positive surgical margins 
(HR = 2.82; 95% IC = [1.06-7.05]; p = 0.04) were 
independent predictors of BCR after RARLP, Table 3. 
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According to Kaplan Meier survival curves, there was 
no significant difference in the 5 year BFSR between 
statin users and non-users (75% versus 73%, respectively; 
p = 0.7).  The statistical power of the study was 0.5 .
Discussion
Because statins decrease the level of cholesterol, they 
have been known for many years to reduce the incidence 
of major vascular events such as myocardial infarction, 
coronary accidents and strokes but their impact on 
prostate carcinogenesis remains controversial.  There 
are biological theories based on experimental data that 
support a potential preventive effect of cholesterol 
lowering treatments against hormone dependent 
cancer progression given that cholesterol is a necessary 
precursor of steroid biosynthesis.19  Furthermore, statins 
might alter prostate cancer cell proliferation considering 
that cholesterol is the major component of lipid rafts 
involved in signaling pathways.  Likewise, the ability 
of statins to induce pro-apoptotic, anti-inflammatory 
and anti-angiogenic effects has also been previously 
well-described in experimental studies.14  Despite 
these encouraging premises, we found that statin use 
was only correlated to pre-operative BMI, which was 
significantly higher among statin users.  Logically, statin 
users are more likely to have diabetes or metabolic 
syndrome both usually linked with an elevated BMI.
Although BCR rate was slightly lower in the statin 
user group in our study, we failed to demonstrate any 
significant difference with the statin non-user group. 
Furthermore, we did not observe any association 
between prognostic factors of prostate cancer and 
statin intake, which suggests that statin medication did 
not influence prostate cancer outcomes after RALRP. 
Our findings are also highlighted by the similar 5 year 
BFSR when comparing statin users and non users.  One 
other flaw could also be the lack of power due to the 
limited number of patients included in each group.
Nevertheless, our findings are consistent with several 
studies in the recent literature.  Recent meta-analysis 
have shown that the overall risk of prostate cancer 
was not reduced by statin use20,21 and several studies 
have reported that cholesterol lowering treatments 
intake had no impact on BCR after radical treatment of 
prostate cancer.14,22  Based on the analysis of data from 
6729 patients included in the REDUCE study, Freedland 
et al observed that men taking statins on a daily basis 
had lower PSA levels, higher BMI and lower serum 
testosterone levels, although differences were low.23  In 
this study, the population was stratified according to 
the D’Amico classification statin use was not associated 
with aggressive pattern of prostate cancer. 
However, some studies have also reported conflicting 
data.  Indeed, Platsz et al demonstrated that statin use 
was correlated to a significant reduced risk of advanced 
prostate cancer.24  These findings were also supported 
in other large studies.25,26  Furthermore, Hamilton et 
al reported a 30% reduction of the risk of BCR among 
statin users but the results were only significant after 
adjustments for drug dosage. 27  Indeed, only a daily 
intake of over 20 mg of simvastatin was associated with 
a reduced risk of BCR after RP.  In our study, we did 
not record these data considering that only statin use 
regardless of statin dose and type was recorded in our 
database.  However it remains a moot point according 
to a recent report.28  Surprisingly, Misrai et al concluded 
that statin use was associated with high risk prostate 
cancer features at diagnosis but with an increased BFSR.15 
In addition, Allott et al reported a reduced risk of BCR 
with postoperative daily intake of statin, after adjusting 
for clinical and pathological characteristics.29  However 
these data came out from retrospective database and must 
be taken with caution.  In addition, some authors have 
recently suggested that BCR might only be delayed by 
statin intake given that cholesterol lowering treatments 
appear to also lower PSA values.27  Indeed, Hamilton 
et al concluded that PSA levels significantly decreased 
after statin initiation but changes in PSA concentrations 
were strongly correlated to statin dose and LDL level.30 
Overall, statin use appeared to lower PSA values by 
only 4% which is more likely to alter initial prostate 
cancer detection than observed time to BCR after 
surgery (i.e.; considering a cut-off value of 0.2 ng/mL as 
a definition of BCR).  Further prospective studies with 
robust methodology are needed to evaluate the clinical 
significance of this effect given that we did not find any 
association between statin use and PSA level.
Conclusions
We acknowledge limitations in our study.  The follow 
up was limited (42.3 months) considering the natural 
history of prostate cancer and a further evaluation 
with a longer follow ups would be interesting to better 
assess the risk of BCR after RALRP.  Lastly, we did not 
take into consideration the type of statin and dosage. 
In the light of our experience, we would not support 
the hypothesis that statins influence the risk of BCR in the 
absence of other meaningful data.  In our study, we found 
no influence of statin medication on clinicopathological 
features of aggressiveness on the specimen and outcomes 
of localized prostate cancer after radical surgery.  Only 
a robust randomized clinical trial would help to make a 
final statement on the impact of statin drugs on prostate 
cancer recurrence after first-line treatment.
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